Profile: CEL-SCI Corp (CVM)
26 Jul 2017
CEL-SCI Corporation, incorporated on March 22, 1983, is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of product candidates and technologies, including Multikine (Leukocyte Interleukin, Injection) (Multikine), an investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus (HIV) and human papillomavirus (HPV) co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for the treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for the treatment of rheumatoid arthritis.
Multikine is being tested in a Phase III clinical trial in primary head and neck cancer. Multikine has been cleared by the regulators in over 20 countries across the world, including the United States. Multikine is also being used in a Phase I study at the Naval Medical Center, San Diego under a cooperative research and development agreement (CRADA) with the United States Navy in HIV/HPV co-infected men and women with peri-anal warts. Multikine is an immunotherapy product candidate consisting of a defined mixture of over 10 human natural cytokines and is manufactured in its manufacturing facility. The first indication the Company is pursuing for its Multikine product candidate is an indication for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN).
Multikine is being developed as a therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase I and Phase II clinical trials suggests that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is designed to be used in a different way than immune therapy is normally used. Multikine is designed to be administered locally to treat local tumors before any other therapy has been administered. In the ongoing Phase III clinical trial, Multikine is injected locally at the site of the tumor and near the adjacent draining lymph nodes as a first line of treatment before surgery, radiation and/or chemotherapy. In clinical studies of Multikine, administration of the investigational therapy to head and neck cancer patients has demonstrated the potential for less or no appreciable toxicity.
The Company also owns and is developing a pre-clinical technology called Ligand Epitope Antigen Presentation System (LEAPS). Its T-cell Modulation Process, referred to as LEAPS, uses heteroconjugates to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to fight bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own. Administered like a vaccine, LEAPS combines T-cell binding ligands with small, disease-associated peptide antigens. The Company is developing over two drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid arthritis therapeutic vaccines.
8229 Boone Blvd Ste 802
VIENNA VA 22182-2634